Open AccessNew Anti-Influenza Agents: Targeting the Virus Entry and Genome Transcription
Author(s) -
Shahla Shahsavandi,
Nikdokht Ebrahimi
Publication year - 2019
Publication title -
majallah-i dānishgāh-i 'ulūm-i pizishkī-i shahīd ṣadūqī yazd/majallah-i dānishgāh-i 'ulūm-i pizishkī va khadamāt-i bihdāshtī-darmānī shahīd ṣadūqī yazd
Language(s) - English
Resource type - Journals
eISSN - 2228-5741
pISSN - 2228-5733
DOI - 10.18502/ssu.v27i7.1932
Subject(s) - virology , virus , genome , biology , pandemic , viral replication , transcription (linguistics) , pandemic influenza , viral entry , influenza a virus , vaccination , gene , covid-19 , medicine , genetics , infectious disease (medical specialty) , disease , linguistics , philosophy , pathology
The emergence and spread of the pandemic H1N1 influenza virus in 2009 indicates a limitation in the strategy to control the infection, despite a long-established vaccination programme and approved antivirals. Production the proper vaccine against influenza is difficult due to the genetic recombination of virus in the event of pandemic and co-circulation of drug-resistance variants highlights the need for the development of new effective and broad-spectrum influenza therapies. Currently, the investigations lie on viral attachment and entry inhibitors, and more attention focuses on viral genome replication and transcription inhibitors in such a way that selective pressure applied by the use of antiviral drugs has covered against all strains. In this review, the novel antiviral agents that targeted the virus-cell membrane attachment, and transcription of the viral genome are discussed